Spero Therapeutics Inc (SPRO) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Spero Therapeutics Inc   (NASDAQ: SPRO)


Spero Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Spero Therapeutics Inc 's ROA in the second quarter of 2026?
Spero Therapeutics Inc achieved a return on average assets (ROA) of 12.57 % in its second quarter of 2026, this is above SPRO's average return on assets of -51.41%.
Spero Therapeutics Inc assets over the 12 months ending in its second quarter of 2026 are valued at $59 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 77 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 161, from total ROA ranking in the first quarter of 2026 at 502.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change -15.06 % -24.05 % -37.96 % -59.92 % -58.37 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 7 15 9 -44 -54
Return On Assets (TTM) 12.57 % 24.95 % 13.04 % -57.47 % -55.53 %
SPRO's Total Ranking # 161 # 502 # 4100 # 4132 # 4256
Total Assets (TTM) in million 53 59 69 54 62
Seq. Total Assets Change -10.6 % -14.36 % 27.23 % -12.8 % -20.06 %
Seq. Net Income Change - - - - -

SPRO's 5 Years Annual ROA >> Back to SPRO Management Effectiveness >> Compare SPRO ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 33
Sector # 78
Overall # 462

Return On Assets Statistics
High Average Low
24.95 %
-51.41 %
-260.11 %
(Mar 31 2026)   (Dec 31 2016)





Financial Statements
Spero Therapeutics Inc 's Assets $ 53 million SPRO's Balance sheet
Spero Therapeutics Inc 's Income $ -10 million Quarterly SPRO's Income Statement
SPRO's Income by Division See SPRO's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -37.5 % -39.48 % 46 % -27.05 % 11.48 %
Total Assets in million 69 110 182 125 171
Y / Y Net Income Change - - - - -
Net Income in million 9 -69 23 -46 -90
Annual Return On Assets 12.44 % -62.18 % 12.52 % -37.19 % -52.47 %

SPRO's 5 Years Annual ROA >> Back to SPRO Management Effectiveness >> Compare SPRO ROA to its Competitors



Comment on SPRO's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 12.44 % compared to prior year, due to annual net income growth of % to $8.57 million, and due to decline of value in Spero Therapeutics Inc 's assets by -37.5 % to $68.92 million, compared to $68.92 a year before.


More Return On Assets Ratios
SPRO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SPRO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SPRO's Competitors
Subscribers only: Roa for Spero Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for SPRO's Customers

You may also want to know
SPRO's Roi SPRO's Inventory Turnover Ratio SPRO's Growth Rates SPRO's Dividend Comparisons
SPRO's Profitability Ratios SPRO's Asset Turnover Ratio SPRO's Dividend Growth
SPRO's Roe SPRO's Valuation Ratios SPRO's Financial Strength Ratios SPRO's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %

Date modified: 2026-09-03T17:21:24+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.